New hope for aggressive breast cancer: targeted drug tested in organ crisis patients
NCT ID NCT07203729
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial tests whether trastuzumab rezetecan (SHR-A1811) works better than standard chemotherapy for people with HER2-Low breast cancer that has spread and is causing severe organ problems (visceral crisis). About 184 participants will receive either the new drug or a standard chemo every three weeks. The study measures how long the cancer stays under control and how well patients respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Trastuzumab rezetecan (SHR-A1811)
- What this could lead to
- If it works, this could offer a more effective treatment option for people with HER2-Low breast cancer that has spread and is causing organ problems.
- What could go wrong
- This is a Phase 2 trial, so it is still early. The drug may not work better than standard chemotherapy, and side effects could be serious.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HER2-LOW UNRESECTABLE/METASTATIC BREAST CANCER COMPLICATED WITH VISCERAL CRISIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, 100021, China